Trial · NCT00445549
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00445549, Phase 2, Terminated, National Cancer Institute (NCI); results first posted 2012-06-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Trials, record NCT00445549. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00445549
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- NCT number
- NCT00445549
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Interventions
- Vandetanib
- First posted
- 2007-03-09
- Last updated
- 2012-06-26
- Results first posted
- 2012-06-26
- Limitations and caveats
- The study closed after the first stage of accrual because of inadequate early activity with 32 cycles of administered treatment.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Clinical Efficacy | 24 weeks | Defined as complete response (CR), partial response (PR), or disease stabilization lasting 6 months or longer per RECIST criteria. CR-total disappearance of all evaluable disease. PR-\>30% reduction in the sum of the longest diameters (LD) of target lesions. Stable disease (SD) is \<30% decrease and \<20% increase in the sum of the LD of all target lesions. See the protocol Link module for full RECIST criteria. |
| Secondary | The Number of Participants With Adverse Events | 22 months | Here are the total # of participants with adverse events. For the detailed list of adverse events, see the adverse event module. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Clinical Efficacy | 24 weeks | participants | NUMBER | |
| SECONDARY | The Number of Participants With Adverse Events | 22 months | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical Efficacy | Vandetanib Treatment | 0 | 1 to 6 | participants | |
| The Number of Participants With Adverse Events | Vandetanib Treatment | 12 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Vandetanib Treatment | 12 | |
| Overall Study | COMPLETED | Vandetanib Treatment | 0 | |
| Overall Study | NOT COMPLETED | Vandetanib Treatment | 12 |
Source ClinicalTrials.gov
Adverse events74
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Vandetanib Treatment | 8 | 12 | 15 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Vandetanib Treatment | 11 | 12 | 16 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Vandetanib Treatment | 9 | 12 | 14 |
| other | Alkaline phosphatase | Investigations | Vandetanib Treatment | 4 | 12 | 6 |
| other | Anorexia | Metabolism and nutrition disorders | Vandetanib Treatment | 5 | 12 | 5 |
| other | Bilirubin (hyperbilirubinemia) | Hepatobiliary disorders | Vandetanib Treatment | 3 | 12 | 8 |
| other | Burn | Injury, poisoning and procedural complications | Vandetanib Treatment | 1 | 12 | 1 |
| other | Calcium, serum-low (hypocalcemia) | Metabolism and nutrition disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Constipation | Gastrointestinal disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Creatinine | Investigations | Vandetanib Treatment | 2 | 12 | 3 |
1 to 10 of 74Source ClinicalTrials.gov
See all 74 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vandetanib Treatment | ||
| Total, other adverse events | Vandetanib Treatment | 12 | 12 |
| Total, serious adverse events | Vandetanib Treatment | 0 | 12 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00445549
GET https://conductscience.org/api/trials/v1/NCT00445549/events?page=2